DUPA (OtBu) -OH

DUPA (OtBu) -OH is a DUPA precursor. DUPA is used as the targeting moiety to actively deliver Docetaxel (DTX) for treatment of Prostate-Specific Membrane Antigen (PSMA) expressing prostate cancer.

Product Specifications

CAS Number

[1026987-94-9]

UNSPSC

12352211

Hazard Statement

H315, H319, H335

Target

PSMA

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/DUPA_OtBu_-OH.html

Purity

98.0

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

O=C(OC(C)(C)C)CC[C@@H](C(OC(C)(C)C)=O)NC(N[C@H](C(OC(C)(C)C)=O)CCC(O)=O)=O

Molecular Formula

C23H40N2O9

Molecular Weight

488.57

Precautions

H315, H319, H335

References & Citations

[1]Roy J, et al. DUPA conjugation of a cytotoxic indenoisoquinoline topoisomerase I inhibitor for selectiveprostate cancer cell targeting. J Med Chem. 2015 Apr 9;58 (7) :3094-103.|[2]Lv Q, et al. Prostate-Specific Membrane Antigen Targeted Therapy of Prostate Cancer Using a DUPA-Paclitaxel Conjugate. Mol Pharm. 2018 May 7;15 (5) :1842-1852.|[3]Peng ZH, et al. Spacer length impacts the efficacy of targeted docetaxel conjugates in prostate-specificmembrane antigen expressing prostate cancer. J Drug Target. 2013 Dec;21 (10) :968-80.